Fracture patterns and associated risk factors in pediatric and early adulthood type 1 diabetes: Findings from a nationwide retrospective cohort study

Rasmussen, Nicklas H.; Driessen, Johanna H.M.; Kvist, Annika Vestergaard; Souverein, Patrick C.; van den Bergh, Joop P.; Vestergaard, Peter

doi:10.1016/j.bone.2023.116997

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This condition is particularly concerning as it markedly increases the likelihood of fractures. Such fractures can lead to high levels of disability, complicating the treatment and rehabilitation process for individuals with diabetes [ 20 , 21 ]. This intersection of diabetes and osteoporosis presents a complex health issue, necessitating more comprehensive and multidisciplinary approaches to management and care.…”

Section: Discussionmentioning

confidence: 99%

Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

Chen,

Lin,

Chen

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

The aim of this study was to investigate the effect of common antidiabetic drugs on BMD by two-sample Mendelian randomization (MR). The single nucleotide polymorphisms that were strongly associated with insulin, metformin, rosiglitazone and gliclazide were extracted as instrumental variables (IVs) for MR analysis. The inverse variance weighted (IVW) method was used as the primary MR method to assess the causal effect of antidiabetic drugs on BMD, and other MR methods, including Weighted median, MR Egger and Weighted mode, were used for complementary analysis. Reliability and stability were assessed by the leave-one-out test. In the present work, IVW estimation of the causal effect of insulin on heel BMD demonstrated that there was a null effect of insulin on heel BMD (β = 0.765; se = 0.971; P = 0.430), while metformin treatment had a positive effect on heel BMD (β = 1.414; se = 0.460; P = 2.118*10−3). The causal relationship between rosiglitazone and heel BMD analysed by IVW suggested that there was a null effect of rosiglitazone on heel BMD (β = -0.526; se = 1.744; P = 0.763), but the causal effect of gliclazide on heel BMD evaluated by IVW demonstrated that there was a positive effect of gliclazide on heel BMD (β = 2.671; se = 1.340; P = 0.046). In summary, the present work showed that metformin and gliclazide have a role in reducing BMD loss in patients with diabetes and are recommended for BMD loss prevention in diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%